title: Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction.
abstract: Monoamine-based treatments for depression have evolved greatly over the past several years, but shortcomings such as suboptimal efficacy, treatment lag, and residual cognitive dysfunction are still significant. Preclinical and clinical studies using compounds directly targeting glutamatergic neurotransmission present new opportunities for antidepressant treatment, with ketamine having a surprisingly rapid and sustained antidepressant effect that is presumably mediated through glutamate-dependent mechanisms. While direct modulation of glutamate transmission for antidepressant and cognition-enhancing actions may be hampered by nonspecific effects, indirect modulation through the serotonin (5-HT) system may be a viable alternative approach. Based on localization and function, 5-HT can modulate glutamate neurotransmission at least through the 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors, which presents a rational pharmacological opportunity for modulating glutamatergic transmission without the direct use of glutamatergic compounds. Combining one or more of these glutamate-modulating 5-HT targets with 5-HT transporter inhibition may offer new therapeutic opportunities. The multimodal compounds vortioxetine and vilazodone are examples of this approach with diverse mechanisms, and their different clinical effects will provide valuable insights into serotonergic modulation of glutamate transmission for the potential treatment of depression and associated cognitive dysfunction.
authors.affiliation: External Sourcing and Scientific Excellence, Lundbeck Research USA, Inc., Paramus, New Jersey, USA.
authors.forename: Alan L
authors.initials: AL
authors.lastname: Pehrson
authors.affiliation: External Sourcing and Scientific Excellence, Lundbeck Research USA, Inc., Paramus, New Jersey, USA.
authors.forename: Connie
authors.initials: C
authors.lastname: Sanchez
mesh_terms: D000818:Animals; D003072:Cognition Disorders / Q000188:drug therapy*; D003863:Depression / Q000188:drug therapy*; D018698:Glutamic Acid / Q000378:metabolism*; D006801:Humans; D012701:Serotonin / Q000378:metabolism*; D018490:Serotonin Agents / Q000627:therapeutic use; D009435:Synaptic Transmission / Q000187:drug effects* / Q000502:physiology
chemical_list: D018490:Serotonin Agents; D012701:Serotonin; D018698:Glutamic Acid
references.citation: Int J Neuropsychopharmacol. 2013 Jun;16(5):1115-27
references.pmid: 23089374
references.citation: J Neurosci. 1995 Mar;15(3 Pt 2):2445-52
references.pmid: 7891179
references.citation: Eur J Pharmacol. 1996 Sep 12;311(2-3):115-9
references.pmid: 8891590
references.citation: Behav Brain Res. 2003 Mar 18;140(1-2):1-47
references.pmid: 12644276
references.citation: Med Hypotheses. 2012 May;78(5):675-81
references.pmid: 22391030
references.citation: Br J Psychiatry. 2001 Mar;178:200-6
references.pmid: 11230029
references.citation: J Neurosci. 2006 Jul 19;26(29):7555-64
references.pmid: 16855083
references.citation: Neuropharmacology. 2004 Mar;46(4):457-67
references.pmid: 14975669
references.citation: Eur J Pharmacol. 2008 Sep 11;592(1-3):96-102
references.pmid: 18634781
references.citation: J Psychopharmacol. 2009 Jun;23(4):343-5
references.pmid: 19433474
references.citation: Biol Psychiatry. 2008 Feb 15;63(4):349-52
references.pmid: 17643398
references.citation: Eur J Pharmacol. 1987 Feb 24;134(3):265-74
references.pmid: 2883013
references.citation: Brain Res Bull. 1995;38(1):17-23
references.pmid: 7552370
references.citation: J Physiol Pharmacol. 2011 Oct;62(5):535-40
references.pmid: 22204801
references.citation: Neuron. 1997 Sep;19(3):687-95
references.pmid: 9331358
references.citation: Neurosci Lett. 2012 Feb 10;509(1):13-6
references.pmid: 22215115
references.citation: Am J Psychiatry. 2012 Nov;169(11):1194-202
references.pmid: 23128924
references.citation: Arch Gen Psychiatry. 2006 Aug;63(8):856-64
references.pmid: 16894061
references.citation: J Affect Disord. 2012 Oct;140(2):113-24
references.pmid: 22088608
references.citation: Psychopharmacology (Berl). 2013 Jul;228(1):157-66
references.pmid: 23455595
references.citation: Neuropharmacology. 2001 Jun;40(8):1028-33
references.pmid: 11406194
references.citation: Psychopharmacology (Berl). 2004 Jun;174(1):39-44
references.pmid: 15205877
references.citation: Am J Psychiatry. 2006 Jan;163(1):153-5
references.pmid: 16390905
references.citation: J Young Pharm. 2012 Oct;4(4):235-44
references.pmid: 23493308
references.citation: J Neurosci. 1987 Feb;7(2):357-68
references.pmid: 2880937
references.citation: Brain Res. 1991 Jun 7;550(2):181-91
references.pmid: 1679370
references.citation: Neurosci Biobehav Rev. 2001 Mar;25(2):193-201
references.pmid: 11323083
references.citation: Br J Psychiatry. 1992 May;160:638-42
references.pmid: 1350494
references.citation: Neurobiol Learn Mem. 1999 Mar;71(2):207-18
references.pmid: 10082640
references.citation: Neurobiol Learn Mem. 2013 Jan;99:25-31
references.pmid: 23137441
references.citation: Int Rev Neurobiol. 2005;64:217-68
references.pmid: 16096024
references.citation: J Clin Psychopharmacol. 1990 Jun;10(3 Suppl):67S-76S
references.pmid: 2198303
references.citation: Curr Med Res Opin. 2012 Oct;28(10):1717-24
references.pmid: 22978748
references.citation: Cereb Cortex. 2004 Oct;14(10):1100-9
references.pmid: 15115744
references.citation: Pharmacol Biochem Behav. 2013 Apr;105:41-50
references.pmid: 23380522
references.citation: Neuropsychopharmacology. 2007 Sep;32(9):1888-902
references.pmid: 17299517
references.citation: Neurosci Lett. 2010 Nov 26;485(3):251-5
references.pmid: 20849926
references.citation: Pharmacol Ther. 2013 Jan;137(1):119-31
references.pmid: 23022360
references.citation: Curr Drug Targets. 2006 Feb;7(2):139-47
references.pmid: 16475955
references.citation: Int Clin Psychopharmacol. 2012 Jul;27(4):215-23
references.pmid: 22572889
references.citation: Neuropsychopharmacology. 2003 Apr;28(4):664-74
references.pmid: 12655311
references.citation: J Clin Psychiatry. 2012 Jul;73(7):953-9
references.pmid: 22901346
references.citation: Psychopharmacology (Berl). 2009 Oct;206(3):345-54
references.pmid: 19649616
references.citation: Behav Pharmacol. 2009 Oct;20(7):662-7
references.pmid: 19741506
references.citation: Psychopharmacology (Berl). 1995 Aug;120(4):409-17
references.pmid: 8539321
references.citation: Sci Transl Med. 2011 Sep 28;3(102):102mr2
references.pmid: 21957170
references.citation: Trends Pharmacol Sci. 2009 Nov;30(11):563-9
references.pmid: 19837463
references.citation: Cereb Cortex. 2012 Jul;22(7):1487-97
references.pmid: 21893679
references.citation: Synapse. 1998 Jul;29(3):257-68
references.pmid: 9635896
references.citation: Eur J Pharmacol. 1996 Dec 30;318(2-3):213-20
references.pmid: 9016908
references.citation: Curr Drug Targets. 2013 May 1;14(5):578-85
references.pmid: 23531115
references.citation: J Clin Psychiatry. 2010 Nov;71(11):1414-5
references.pmid: 21114946
references.citation: Neuropsychopharmacology. 2008 Aug;33(9):2080-92
references.pmid: 18172433
references.citation: Synapse. 1987;1(1):3-9
references.pmid: 3505364
references.citation: Am J Psychiatry. 1993 Nov;150(11):1731-3
references.pmid: 8214185
references.citation: Neuropsychopharmacology. 2004 Jul;29(7):1259-69
references.pmid: 15010696
references.citation: Eur Neuropsychopharmacol. 2006 May;16(4):297-310
references.pmid: 16288851
references.citation: IDrugs. 2007 Mar;10(3):193-201
references.pmid: 17351874
references.citation: Behav Brain Res. 2012 Oct 1;234(2):238-47
references.pmid: 22789402
references.citation: CNS Neurol Disord Drug Targets. 2007 Apr;6(2):117-26
references.pmid: 17430149
references.citation: Cereb Cortex. 2004 Dec;14(12):1365-75
references.pmid: 15166106
references.citation: Psychopharmacology (Berl). 2009 Oct;206(3):403-14
references.pmid: 19629447
references.citation: Neuropsychopharmacology. 2013 Apr;38(5):729-42
references.pmid: 23303054
references.citation: Neuroscience. 2011 Sep 8;190:328-38
references.pmid: 21684321
references.citation: Neuropsychopharmacology. 2001 Mar;24(3):209-29
references.pmid: 11166513
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1558-68
references.pmid: 20600468
references.citation: Science. 2006 Jan 6;311(5757):77-80
references.pmid: 16400147
references.citation: J Affect Disord. 2011 Nov;134(1-3):20-31
references.pmid: 21163534
references.citation: J Med Chem. 2011 May 12;54(9):3206-21
references.pmid: 21486038
references.citation: Int J Neuropsychopharmacol. 2013 Mar;16(2):313-21
references.pmid: 22963932
references.citation: Br J Pharmacol. 2003 Jan;138(1):71-80
references.pmid: 12522075
references.citation: PLoS One. 2011;6(6):e20210
references.pmid: 21701689
references.citation: BMC Psychiatry. 2007 Jul 17;7:32
references.pmid: 17634111
references.citation: Mol Psychiatry. 2008 Nov;13(11):1011-20
references.pmid: 17955021
references.citation: Brain Res. 1996 May 20;721(1-2):59-65
references.pmid: 8793084
references.citation: Int Clin Psychopharmacol. 2012 Jul;27(4):197-207
references.pmid: 22475889
references.citation: Science. 2010 Aug 20;329(5994):959-64
references.pmid: 20724638
references.citation: Curr Med Res Opin. 2013 Mar;29(3):217-26
references.pmid: 23252878
references.citation: Nat Neurosci. 2013 Apr;16(4):464-72
references.pmid: 23502536
references.citation: Acta Psychiatr Scand. 1998 Apr;97(4):302-8
references.pmid: 9570492
references.citation: Am J Psychiatry. 2004 Nov;161(11):2132
references.pmid: 15514421
references.citation: Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):181-94
references.pmid: 15180479
references.citation: Neuropsychopharmacology. 2005 Jul;30(7):1269-77
references.pmid: 15702136
references.citation: Biol Psychiatry. 2007 Dec 1;62(11):1310-6
references.pmid: 17574216
references.citation: J Neurosci. 1997 May 1;17(9):3157-67
references.pmid: 9096150
references.citation: Neuroscience. 2009 Sep 15;162(4):1091-100
references.pmid: 19410634
references.citation: CNS Spectr. 2013 Aug;18(4):188-98
references.pmid: 23369807
references.citation: Biol Psychiatry. 2000 Apr 1;47(7):586-93
references.pmid: 10745050
references.citation: CNS Neurosci Ther. 2012 Apr;18(4):302-12
references.pmid: 22070796
references.citation: J Psychopharmacol. 2012 Nov;26(11):1408-16
references.pmid: 22495621
references.citation: J Psychopharmacol. 1995 Jan;9(3):242-50
references.pmid: 22297764
references.citation: Curr Neuropharmacol. 2006 Oct;4(4):313-39
references.pmid: 18654635
references.citation: J Pharmacol Exp Ther. 2007 May;321(2):690-8
references.pmid: 17314195
references.citation: Br J Psychiatry. 2009 Jun;194(6):535-40
references.pmid: 19478294
references.citation: Eur Neuropsychopharmacol. 2007 Feb;17(3):172-9
references.pmid: 16630709
references.citation: Eur Neuropsychopharmacol. 2013 Feb;23(2):133-45
references.pmid: 22612991
references.citation: Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600
references.pmid: 21767441
references.citation: Neuropharmacology. 2004 Jun;46(7):907-17
references.pmid: 15081787
references.citation: Biol Psychiatry. 2010 Nov 1;68(9):785-94
references.pmid: 20728076
references.citation: Am J Psychiatry. 2004 Jan;161(1):171-4
references.pmid: 14702270
references.citation: Brain Res. 2010 Dec 17;1366:110-9
references.pmid: 20920493
references.citation: Am J Psychiatry. 2009 Sep;166(9):980-91
references.pmid: 19687129
references.citation: Int J Psychiatry Clin Pract. 2013 Aug;17(3):160-9
references.pmid: 23578403
references.citation: J Neurophysiol. 1997 Jan;77(1):517-21
references.pmid: 9120594
references.citation: J Chem Neuroanat. 2008 Sep;36(1):17-26
references.pmid: 18572381
references.citation: Biol Psychiatry. 2000 Feb 15;47(4):351-4
references.pmid: 10686270
references.citation: Methods Find Exp Clin Pharmacol. 1997 Jan-Feb;19(1):43-6
references.pmid: 9098839
references.citation: Expert Opin Ther Targets. 2005 Feb;9(1):153-68
references.pmid: 15757488
references.citation: Neurosci Biobehav Rev. 2004 Oct;28(6):565-82
references.pmid: 15527863
references.citation: Brain Res Bull. 2012 Aug 1;88(5):477-86
references.pmid: 22542420
references.citation: J Med Chem. 2004 Sep 9;47(19):4684-92
references.pmid: 15341484
references.citation: J Clin Psychiatry. 2002 Apr;63(4):337-44
references.pmid: 12000208
references.citation: Eur J Neurosci. 2002 Jul;16(2):209-18
references.pmid: 12169103
references.citation: J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7
references.pmid: 12183683
references.citation: Neuropsychopharmacology. 2008 Aug;33(9):2175-86
references.pmid: 18033238
references.citation: Behav Pharmacol. 2004 Dec;15(8):523-34
references.pmid: 15577451
references.citation: Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16720-5
references.pmid: 23012427
references.citation: Cephalalgia. 1999 Dec;19(10):859-65
references.pmid: 10668104
references.citation: Brain Res. 2003 Jan 3;959(1):58-67
references.pmid: 12480158
references.citation: Eur Neuropsychopharmacol. 2010 Sep;20(9):641-54
references.pmid: 20488670
references.citation: Psychopharmacology (Berl). 2012 May;221(2):205-15
references.pmid: 22227609
references.citation: Br J Pharmacol. 2009 Jan;156(2):338-53
references.pmid: 19154445
references.citation: Trends Pharmacol Sci. 2004 Sep;25(9):481-6
references.pmid: 15559250
references.citation: J Psychopharmacol. 1998;12(2):115-21
references.pmid: 9694022
references.citation: Eur J Pharmacol. 1995 Oct 24;285(3):221-8
references.pmid: 8575507
references.citation: Biol Psychiatry. 2002 Feb 1;51(3):253-60
references.pmid: 11839368
references.citation: Neuropharmacology. 1997 Jul;36(7):961-71
references.pmid: 9257940
references.citation: Eur Neuropsychopharmacol. 2012 Jul;22(7):482-91
references.pmid: 22209361
references.citation: Eur J Pharmacol. 2002 Apr 5;440(1):27-35
references.pmid: 11959085
references.citation: J Clin Psychopharmacol. 2008 Dec;28(6):631-7
references.pmid: 19011431
references.citation: Eur J Pharmacol. 1992 Feb 25;212(1):73-8
references.pmid: 1532555
references.citation: Brain Res. 2003 Dec 12;993(1-2):230-4
references.pmid: 14642852
references.citation: Arch Psychiatr Nervenkr (1970). 1982;232(4):299-304
references.pmid: 6133511
references.citation: Curr Pharm Des. 2006;12(28):3615-30
references.pmid: 17073663
references.citation: Neuropharmacology. 2012 Jan;62(1):63-77
references.pmid: 21827775
references.citation: Brain Res. 1989 Aug 14;494(2):315-24
references.pmid: 2570624
references.citation: J Pharmacol Exp Ther. 2011 Aug;338(2):605-14
references.pmid: 21558435
references.citation: J Neurosci. 1997 Jul 15;17(14):5591-8
references.pmid: 9204940
references.citation: Neuropharmacology. 2008 Jun;54(7):1041-50
references.pmid: 18394658
references.citation: Pharmacol Biochem Behav. 1992 May;42(1):75-83
references.pmid: 1388279
references.citation: Behav Brain Res. 2004 Dec 6;155(2):275-82
references.pmid: 15364487
references.citation: J Clin Psychiatry. 2004 Jun;65(6):791-804
references.pmid: 15291656
references.citation: Annu Rev Clin Psychol. 2005;1:167-95
references.pmid: 17716086
references.citation: Consult Pharm. 2012 Dec;27(12):857-67
references.pmid: 23229074
references.citation: J Pharmacol Exp Ther. 2012 Mar;340(3):666-75
references.pmid: 22171087
references.citation: Behav Brain Res. 2012 Mar 1;228(1):211-8
references.pmid: 22189656
references.citation: Neuropsychopharmacology. 1999 Aug;21(2 Suppl):91S-98S
references.pmid: 10432494
references.citation: Br J Pharmacol. 2010 Aug;160(8):1929-40
references.pmid: 20649591
references.citation: Behav Brain Res. 2012 Jan 1;226(1):118-23
references.pmid: 21925545
references.citation: CNS Spectr. 2010 Feb;15(2):79-94
references.pmid: 20414154